ESOC 2023 – oral presentation
📢Lys Therapeutics is glad to announce presenting during the European Stroke Organization Congress happening this week in Munich its last results in ischemic #stroke demonstrating the #synergy of its lead #drug with #alteplase or #tenecteplase including the extension of their therapeutic window far beyond the currently limited 0h to 4h30 period.
“Glunomab: A Monoclonal Antibody Counteracting The Neurovascular And Neuroinflammatory Damages Induced Both By Endogenous Tpa And Fibrinolytic Agents (Alteplase Or Tenecteplase) After Ischemic Stroke”
🎤 Speaker: Manuel BLANC, CEO
📅 Wednesday, 24 May, 09:20 CEST
📍 Room 14 – Plenary / Session: IV Thrombolysis
With Jean-Baptiste BERTRAND, head of Clinical Operations